Non-Invasive Screening for Fetal Aneuploidy

NCT02317965 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 340

Last updated 2018-08-28

No results posted yet for this study

Summary

The purpose of this study is to detect whole chromosome abnormalities in maternal blood.

Conditions

  • Down Syndrome
  • Edwards Syndrome

Interventions

OTHER

Maternal Blood Draw

Maternal Blood Draw

Sponsors & Collaborators

  • Obstetrix Medical Group

    collaborator INDUSTRY
  • Progenity, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Porreco, MD · Obstetrix Medical Group of Colorado

  • Thomas Garite, MD · Obstetrix Medical Group

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02317965 on ClinicalTrials.gov